| Literature DB >> 26866373 |
Zhao Gao1,2, Yu Han1,2, Yunhui Hu1,2, Xiaoyan Wu1,2, Yongbin Wang1,2, Xiaoqun Zhang1,2, Jinjuan Fu1,2, Xue Zou1,2, Jun Zhang1,2, Xiongwen Chen1,2, Pedro A Jose3,4, Xi Lu1,2, Chunyu Zeng1,2.
Abstract
Both oxidative stress and inflammation are involved in the pathogenesis of contrast-induced nephropathy (CIN). Epigallocatechin-3-gallate (EGCG), a purified catechin from green tea, has antioxidant and anti-inflammatory effects. However, it is unknown whether or not EGCG is effective in treating CIN. Our present study found that intravenous administration of EGCG, either before or just after the establishment of CIN, had a protective effect, determined by normalization of serum creatinine and blood urea nitrogen levels, improvement in renal histopathological scoring and alleviation of apoptosis, accompanied by decreased oxidative stress and inflammation. Because EGCG is a potent inducer of the antioxidant heme oxygenase-1 (HO-1), we studied HO-1 signaling in CIN. HO-1 levels were increased in CIN; treatment with EGCG further increased HO-1 levels, accompanied by an increase in Nrf2, a regulator of antioxidant proteins. Interestingly, blockade of HO-1 with protoporphyrin IX zinc(II) (ZnPP) prevented the protective effect of EGCG on CIN. ZnPP also blocked the ability of EGCG to increase the activity of an antioxidant (superoxide dismutase), and decrease markers of oxidative stress (myeloperoxidase and malondialdehyde) and inflammation (myeloperoxidase and IL-1β), indicating that HO-1 is the upstream molecule that regulates the EGCG-mediated protection. To determine further the role of HO-1 on the EGCG-mediated inhibition of inflammation, we studied the effect of EGCG on the NLRP3 inflammasome, an upstream signaling of IL-1β. EGCG down-regulated NLRP3 expression, which was blocked by ZnPP, indicating that HO-1 links EGCG with NLRP3. Therefore, EGCG, via up-regulation of HO-1, protects against CIN by amelioration of oxidative stress and inflammation.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26866373 PMCID: PMC4750900 DOI: 10.1371/journal.pone.0149032
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Establishment of CIN in rats and renal protective effect of EGCG on CIN.
The rats sequentially received an intravenous infusion of indomethacin, L-NAME, and iopromide to establish CIN. Serum Cr (A) and BUN (B) concentrations were measured 24h, 48h, and 72h after the intravenous injections. Varying dosages of EGCG (5, 10, 20mg/kg body wt) were administered intravenously 15min before the establishment of CIN. Serum Cr (C), BUN (D) and CrCL (E) were measured 24h after the establishment of CIN. (n = 5, * P<0.05 vs. vehicle; # P<0.05 vs. CM).
Fig 2Renal protective effect of EGCG on medullary damage and apoptosis in CIN kidney.
EGCG (10mg/kg body wt) was given intravenously 15min before (pre-EGCG+CM) or after the establishment of CIN (post-EGCG+CM). Serum Cr (A) and BUN (B) were measured 24h after the establishment of CIN. (C) Representative images of H&E staining under ×400 magnification in the outer medulla. Arrows showed examples of protein casts and tubular vacuolar degeneration/necrosis. Erythrocytes and infiltration of polymorphonuclear cells could be easily observed in the interstitium. (D) Representative images of TUNEL assay under ×400 magnification in the outer medulla. (E) The histopathologic scores of medullary damage. (F) Quantification of TUNEL-positive nuclei per ×200 field. (n = 5, * P<0.05 vs. vehicle; # P<0.05 vs. CM).
Fig 3Role of HO-1 in the antioxidant and renal protective effect of EGCG in CIN.
EGCG (10mg/kg body wt) was intravenously infused 15min before the establishment of CIN. The HO-1 inhibitor ZnPP (30mg/kg body wt) was injected intraperitoneally 7h before EGCG pretreatment. The rats were sacrificed at 24h after the establishment of CIN. Renal MDA level (A) and SOD activity (B) were measured. Renal HO-1 protein detected by immunoblotting was expressed as the ratio of HO-1 and GAPDH (C). Serum Cr (D), and BUN (E) were determined to evalute the renal function. Nrf2 expression in the nuclear fraction of renal tissue detected by immunoblotting was expressed as the ratio of Nrf2 and histone H3 (F). (n = 5, * P<0.05 vs. vehicle; # P<0.05 vs. CM; & P<0.05 vs. EGCG).
Fig 4Role of HO-1 in the anti-inflammatory effect of EGCG in CIN.
EGCG (10mg/kg body wt) was intravenously infused 15min before the establishment of CIN. The HO-1 inhibitor ZnPP (30mg/kg body wt) was injected intraperitoneally 7h before EGCG pretreatment. The rats were sacrificed at 24h after the establishment of CIN. Renal MPO activity (A) and IL-1βlevel (B) were measured. Renal NLRP3 protein expression was detected by immunofluorescence microscopy (red fluorescence, ×400) (C), and semi-quantified by immunoblotting, expressed as the ratio of NLRP3 and GAPDH (D). (n = 5, * P<0.05 vs. vehicle; # P<0.05 vs. CM; & P<0.05 vs. EGCG).
Fig 5Schematic diagram of possible mechanism of EGCG in protecting against CIN.
HO-1 expression is markedly enhanced by EGCG via activation of the Nrf2/HO-1 pathway. HO-1 is essential to the protective effect of EGCG on CIN in anti-oxidation and anti-inflammation. Dash-line arrow stands for unclear or multiple-step actions. Straight-line arrow stands for direct actions.